Relapsed neuroblastoma is common, frequently lethal and poorly studied and poses a major treatment challenge. Two new studies shed light on the genomic landscape of recurrent neuroblastoma and demonstrate profound differences between the disease at diagnosis and relapse.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Precision medicine in pediatric oncology
Molecular and Cellular Pediatrics Open Access 31 August 2018
-
Neuroblastoma treatment in the post-genomic era
Journal of Biomedical Science Open Access 08 February 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pugh, T.J. et al. Nat. Genet. 45, 279–284 (2013).
Mossé, Y.P. et al. Lancet Oncol. 14, 472–480 (2013).
Eleveld, T.F. et al. Nat. Genet. 47, 864–871 (2015).
Schramm, A. et al. Nat. Genet. 47, 872–877 (2015).
Gerlinger, M. et al. Nat. Genet. 46, 225–233 (2014).
Aparicio, S. & Caldas, C. N. Engl. J. Med. 368, 842–851 (2013).
Sinha, G. J. Natl. Cancer Inst. 100, 84–85 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ramaswamy, V., Taylor, M. Pediatric cancer genomics, a play rather than a portrait. Nat Genet 47, 851–852 (2015). https://doi.org/10.1038/ng.3366
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3366
This article is cited by
-
Precision medicine in pediatric oncology
Molecular and Cellular Pediatrics (2018)
-
Neuroblastoma treatment in the post-genomic era
Journal of Biomedical Science (2017)